[{"orgOrder":0,"company":"Cantoni Therapeutics","sponsor":"Brabant Development Agency","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"NNMT","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Cantoni Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantoni Therapeutics \/ Brabant Development Agency","highestDevelopmentStatusID":"4","companyTruncated":"Cantoni Therapeutics \/ Brabant Development Agency"}]

Find Clinical Drug Pipeline Developments & Deals by Cantoni Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The financing will be used to advance company's lead asset, a small molecule inhibitor of NNMT, into IND enabling phase for obesity and its comorbidities.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 16, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Brabant Development Agency

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank